Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509548 · ClinicalTrials.gov registry record · Phase 2
Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
A Phase 2 study, sponsored by TargeGen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00509548: Clinical Trial Phase 2 study, sponsored by TargeGen.
NCT00509548 is a Phase 2 study that was terminated before completion, run by TargeGen. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00509548, a Phase 2 study, was terminated before completion, sponsored by TargeGen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina. The build-up of fluid (edema) under the macula can distort vision or cause vision loss. TG100801 is a topical (eye drop) therapy that has been shown to inhibit ocular angiogenesis, vascular leak, and inflammation in laboratory studies. The primary purpose of this pilot study is to evaluate the ability of topical administration of TG100801 to reduce the amount of fluid in the retina in patients with AMD following 30 days of treatment. An additional objective is to evaluate the safety of TG100801 in patients with AMD.
Interventions
- DRUG TG100801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Why NCT00509548 stopped before completion
NCT00509548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which TG100801 is the first listed.
NCT00509548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00509548 about?
NCT00509548 is a clinical study titled "Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD". Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina. The build-up of fluid (edema) under the macula can distort vision or cause vision loss...
What is the current status of trial NCT00509548?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-07. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00509548?
The interventions under investigation include: TG100801 (DRUG).
Who is sponsoring clinical trial NCT00509548?
This trial is sponsored by TargeGen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00509548's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia